

## Exploring Key Issues Affecting the Care of Patients with Metastatic Colorectal Cancer with BRAF Mutations (Faculty Presentation)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding overall survival (OS) results from the Phase III BEACON CRC study evaluating encorafenib and cetuximab with or without binimetinib versus investigator's choice of either irinotecan with cetuximab or FOLFIRI with cetuximab for patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutations who had experienced disease progression after 1 or 2 previous regimens?**
  - a. The triplet regimen of encorafenib, binimetinib and cetuximab did NOT result in an OS improvement in comparison to the control therapy
  - b. The doublet regimen of encorafenib and cetuximab did NOT result in an OS improvement in comparison to the control therapy
  - c. Encorafenib with cetuximab with or without binimetinib resulted in OS improvements in comparison to the control arm**
- 2. Which of the following statements is FALSE regarding the clinical implications of the BEACON CRC study, which investigated encorafenib and cetuximab with or without binimetinib versus investigator's choice of either irinotecan and cetuximab or FOLFIRI and cetuximab for patients with BRAF V600E-mutant mCRC who had experienced disease progression after 1 or 2 previous regimens?**
  - a. MEK inhibition improves the depth of response to cetuximab-combination therapy
  - b. MEK inhibition improves the duration of benefit from cetuximab-combination therapy**
  - c. Early administration of treatment may result in better outcomes
- 3. Presentation at ESMO 2021 of the ANCHOR CRC trial evaluating the combination of encorafenib, binimetinib and cetuximab as first-line therapy for patients with mCRC with BRAF V600E mutations reported which of the following outcomes?**
  - a. The study did NOT meet its primary endpoint in terms of confirmed objective response rate (cORR)
  - b. The study met its primary endpoint in terms of cORR**
- 4. The Phase III BREAKWATER trial is comparing encorafenib and cetuximab with or without chemotherapy to standard chemotherapy in which setting for patients with mCRC with BRAF V600E mutations?**
  - a. First line**
  - b. Second line
  - c. Third and later line